Coronary drug project

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Official Title

Coronary Drug Project

Objective

To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Timeline
Start Date	April 1965
End Date	March 1985
Status	Completed

The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT00000482.

Study Description

Study Description
Study Type	Interventional
Study Phase	Phase 3
Study Design
Allocation	Randomized
Masking	Double-Blind
Study Details
Primary Purpose	Prevention
Condition	Cardiovascular diseases; coronary disease; heart diseases; myocardial infarction; myocardial ischemia
Intervention	Drug: estrogen Drug: clofibrate clofibrate Drug: dextrothyroxine sodium Drug: niacin
Population Size	8,341 subjects

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00000482.

Eligibility Criteria

Inclusion Criteria

Men, ages 30-64, three months beyond most recent myocardial infarction

References